Clinical Trial Update: An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating golimumab for moderately to severely active ulcerative colitis; the study is completed and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 3 | Status: COMPLETED | Results posted: 2013-11-11